Tudor Investment Corp ET AL Invests $3.67 Million in AbCellera Biologics Inc. $ABCL

Key Points

• Tudor Investment Corp ET AL opened a new Q3 position in AbCellera (NASDAQ:ABCL), buying 730,122 shares worth about $3.67 million, or roughly 0.24% of the company.
• Other institutions notably increased or initiated stakes — including Two Sigma (5.175M shares, ~$26.03M) and Bank of America (up 977.8% to 2.418M shares, ~$12.16M) — and institutional investors now own about 61.42% of ABCL.
• AbCellera trades near $3.44 with a market cap of ~$1.04B; it reported Q results showing $44.85M revenue and EPS of -$0.03 (both beating expectations), while analysts have a consensus Hold rating and an average target of $7.75.

Tudor Investment Corp ET AL bought a new position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 730,122 shares of the company's stock, valued at approximately $3,673,000. Tudor Investment Corp ET AL owned about 0.24% of AbCellera Biologics as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of ABCL. Bank of America Corp DE lifted its stake in shares of AbCellera Biologics by 977.8% during the 3rd quarter. Bank of America Corp DE now owns 2,418,304 shares of the company's stock worth $12,164,000 after buying an additional 2,193,939 shares during the last quarter. Two Sigma Investments LP lifted its stake in shares of AbCellera Biologics by 25.9% during the 3rd quarter. Two Sigma Investments LP now owns 5,175,142 shares of the company's stock worth $26,031,000 after buying an additional 1,064,290 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in shares of AbCellera Biologics during the 3rd quarter worth about $3,707,000. Jump Financial LLC acquired a new stake in shares of AbCellera Biologics during the 3rd quarter worth about $3,398,000. Finally, DNB Asset Management AS acquired a new stake in shares of AbCellera Biologics during the 3rd quarter worth about $3,301,000. Institutional investors and hedge funds own 61.42% of the company's stock.

AbCellera Biologics Stock Up 0.3%

Shares of AbCellera Biologics stock opened at $3.44 on Friday. AbCellera Biologics Inc. has a twelve month low of $1.94 and a twelve month high of $6.51. The company has a 50-day simple moving average of $3.38 and a two-hundred day simple moving average of $4.04. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -7.02 and a beta of 0.85.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.15. AbCellera Biologics had a negative net margin of 198.37% and a negative return on equity of 15.05%. The business had revenue of $44.85 million during the quarter, compared to analysts' expectations of $6.31 million. On average, sell-side analysts anticipate that AbCellera Biologics Inc. will post -0.59 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Wall Street Zen upgraded shares of AbCellera Biologics from a "sell" rating to a "hold" rating in a research note on Saturday, February 14th. Weiss Ratings reiterated a "sell (d-)" rating on shares of AbCellera Biologics in a research note on Wednesday, January 21st. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $7.75.

AbCellera Biologics Profile

AbCellera Biologics Inc NASDAQ: ABCL is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company's technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.